Biotech Startups

Oxurion is a French specialist in clinical biometrics and data management, providing the core technology for the Oxurion platform.

1 investor

OzoneBio engineers biologically-powered materials to replace fossil-based chemical production processes for industrial applications. The company targets the chemical manufacturing industry with sustainable alternatives designed for performance and environmental responsibility.

1 investor

P95 is a clinical research and pharmaceutical services company that supports pharmaceutical development through medical monitoring, epidemiology, biostatistics, study management, pharmacovigilance, and medical writing services.

1 investor

P-Mind develops non-invasive therapeutic technologies based on decades of research into magnetic fields and their interaction with living organisms, with a focus on treating pain disorders, neurological diseases, and cancer. The company manufactures and sells medical devices, including the alternating magnetic field therapy device "Eight" (エイト).

1 investor

P3 Therapeutics is developing a new class of anti-inflammatory small chemical molecules and works with partners on a humanized gut-entheseal organ-on-chip platform to study their mechanism of action, pharmacokinetics, pharmacodynamics, and biomarkers. The work is part of an application to the EUROSTARS 3 program under the TRIGG3R project.

1 investor

Pacific Biosciences manufactures consumables and reagent kits for long-read DNA and RNA sequencing platforms, serving genomics research and diagnostics labs.

1 investor

1 investor

Pace provides laboratory testing services to help customers assess environmental safety and health risks. Founded in 1978, the company serves organizations needing accurate testing and is committed to sustainable practices and regulatory compliance.

1 investor

Pacific Hybreed develops commercial shellfish breeding programs and genetics tools to improve yield and disease resilience for U.S. West Coast aquaculture. The company applies shellfish genetics research to make farmed shellfish more resilient to climate change, ocean acidification, and disease.

1 investor

Pacify Medical develops biomedical devices for wound management, specifically surgical and trauma wound care. The company's flagship product is a patent-protected skin spray device designed to improve wound healing outcomes.

1 investor

Pacira develops and commercializes non-opioid therapies for postsurgical, chronic, and musculoskeletal pain, and is advancing a gene therapy pipeline candidate. It serves patients and healthcare providers seeking alternatives to opioid pain management.

1 investor

PACIV provides industrial automation controls, instrumentation, and system validation services for biotechnology, pharmaceutical, medical device, food & beverage, and utilities sectors. The company operates across the United States, Puerto Rico, and Ireland with local teams supporting client-specific automation platform implementations.

1 investor

PAhR Therapeutics is a clinical-stage biotech company developing novel mechanisms to treat pulmonary arterial hypertension (PAH).

1 investor

1 investor

PAION AG is a company whose business operations were sold in a finalised sale process in early 2024. The available page content consists of investor news announcements and does not describe the company's products or activities in detail.

1 investor

Pairidex offers FusionMRD, a personalized digital droplet PCR (ddPCR) assay that detects and quantifies oncogenic gene fusions from a standard peripheral blood sample to monitor treatment response and minimal residual disease in gene fusion-driven blood cancers such as leukemia. It is sold as a commercial service for oncologists and clinical researchers to support treatment decisions and shorten clinical trial timelines.

1 investor

PAK BioSolutions builds automated systems and single-use flow kits for end-to-end continuous purification of biopharmaceuticals, running four continuous purification stages simultaneously for a stated 4X productivity gain over batch methods. Its equipment and GMP consumables serve biopharmaceutical manufacturers for both laboratory and GMP production.

1 investor

Paleo develops plant-based protein products designed to replicate the taste and qualities of animal meat, addressing sustainability in food production. The company targets food producers and consumers seeking sustainable protein alternatives.

1 investor

Palisade Bio develops a PDE4 prodrug platform for treating immune, inflammatory, and fibrotic diseases, with improved pharmacokinetics and tolerability compared to traditional PDE4 inhibitors. The company's lead candidate is designed for once-daily dosing with reduced gastrointestinal side effects.

1 investor

1 investor

Palland Tx is developing next-generation targeted protein degraders aimed at improving therapeutic efficacy through precision targeting. The company operates in the biotech and therapeutics space, though its website is still in a pre-launch "coming soon" state.

1 investor

1 investor

Palm Therapeutics develops palmitoylation-targeted drugs using its proprietary PalmReader screening platform to identify novel therapeutic molecules. The company focuses on modulating protein palmitoylation, a post-translational modification involved in multiple disease pathways.

1 investor

Palto Therapeutics develops formulations for biological drugs, focusing on oligonucleotide therapeutics such as siRNAs and antisense oligonucleotides that deliver directly into diseased cells and activate in the cytoplasm. It works on proprietary delivery and formulation strategies aimed at addressing in vivo stability and targeted tissue/cell distribution for these next-generation drugs.

1 investor